The global neonatal toxicology market was valued at USD 10.64 billion in 2024 and is estimated at USD 11.44 billion in 2025. It is projected to reach USD 22.22 billion by 2034, advancing at a CAGR of 7.65% during the forecast period 2025–2034. Rising maternal substance use and expanding neonatal and maternal healthcare infrastructure underpin this growth. Leading participants include Agilent Technologies, Inc., ARUP Laboratories, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific SE, Labcorp Holdings, Inc., QuidelOrtho Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and United States Drug Testing Laboratories, Inc. (USDTL).

Specimen Selection Defines Testing Strategy

The neonatal toxicology market includes laboratory testing, diagnostic services, and monitoring solutions that detect newborn exposure to toxic substances before birth or after delivery. These solutions are applied in clinical laboratories, neonatal intensive care units, and hospitals to identify exposure to drugs, alcohol, and environmental toxins so that treatment can begin early. By specimen, the market is classified into urine, umbilical cord, meconium, and others. Meconium held a major share in 2024 because it offers a longer detection window for prenatal drug exposure. Umbilical cord tissue is projected to grow rapidly owing to its faster turnaround time immediately after birth, positioning umbilical cord tissue testing as a high-growth specialty.

Browse Full Insights: https://www.polarismarketresearch.com/industry-analysis/neonatal-toxicology-market

Technology Platforms: Immunoassay and Mass Spectroscopy

By technology, the market is categorized into mass spectroscopy and immunoassay. The immunoassay segment dominated in 2024 due to wide clinical adoption, faster processing time, and cost-effectiveness for routine programs, which makes immunoassay screening a common choice within neonatal drug screening programs. Mass spectroscopy is estimated to grow at a fast pace thanks to its superior accuracy, specificity, and capability to detect low-concentration drug metabolites in complex neonatal samples. Technological advancement in both platforms is enabling quicker and more accurate identification of drugs, alcohol, and environmental poisons, supporting timely interventions and improved clinical responses.

Regional Outlook for the Neonatal Toxicology Market

North America led the global market in 2024, driven by a high incidence of neonatal exposure to drugs such as opioids and prescription medications. The U.S. contributed the most in the region on widespread use of neonatal intensive care units and advanced neonatal healthcare infrastructure; according to the U.S. Centers for Disease Control and Prevention, every state operates a newborn screening program. Europe benefits from well-developed neonatal infrastructure, including specialist NICUs that allow early identification of drug exposure. Asia Pacific is expected to see high growth on rising awareness among healthcare providers and parents, with India leading the region. In September 2025, Reckitt, PATH, and the Centre for Health Research and Innovation launched the Dettol Banega Swasth India Maternal and Child Health Tech Accelerator.

Drivers Behind Market Expansion

Growth in neonatal and maternal healthcare infrastructure is increasing demand for sophisticated testing solutions, with hospitals, neonatal intensive care units, and specialized clinics broadening access to screening. Increasing R&D investment is propelling new testing kits, screening platforms, and point-of-care diagnostics, making it easier and quicker for healthcare professionals to detect toxic substances in newborns. By end use, hospitals dominated in 2024 as the primary centers for immediate screening and early intervention, while clinical laboratories are projected to grow rapidly on advanced confirmatory toxicology. In Asia Pacific, adoption of lab-based screening solutions and advanced neonatal care practices is rising in emerging economies, supporting better health outcomes.

Competitive Dynamics and Restraints

The Neonatal Toxicology market is moderately competitive, with players advancing toxicology screening, biomarker-based diagnostics, and precision testing, including LC-MS/MS and high-sensitivity immunoassay technologies. In January 2025, Brown Gibbons Lang & Company announced the sale of USDTL to Northlane Capital Partners, and in August 2024 Labcorp completed the acquisition of select assets from Invitae to enhance its diagnostic capabilities. The high price of sophisticated diagnostic equipment and reagents remains a restraint, particularly for smaller hospitals and developing regions.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market